Edition:
United Kingdom

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

270.39USD
24 May 2019
Change (% chg)

$7.75 (+2.95%)
Prev Close
$262.64
Open
$262.97
Day's High
$272.75
Day's Low
$262.83
Volume
224,812
Avg. Vol
227,777
52-wk High
$458.50
52-wk Low
$228.00

Latest Key Developments (Source: Significant Developments)

FDA Confirms Impella Rp Is Safe And Effective Only Right-Sided Device With FDA Approval
Tuesday, 21 May 2019 

May 21 (Reuters) - Abiomed Inc ::FDA CONFIRMS IMPELLA RP IS SAFE AND EFFECTIVE; ONLY RIGHT-SIDED DEVICE WITH FDA APPROVAL.ABIOMED INC - FDA CONFIRMS IMPELLA RP IS SAFE AND EFFECTIVE.ABIOMED INC - 18-MONTH PAS REPORT HAS BEEN ACCEPTED BY FDA AND IS SUCCESSFULLY CLOSED..ABIOMED INC - FDA HAS NO SAFETY CONCERNS ABOUT IMPELLA RP ITSELF.  Full Article

Abiomed Q4 GAAP Earnings Per Share $1.60
Thursday, 2 May 2019 

Abiomed Inc ::ABIOMED ANNOUNCED Q4 FY 2019 REVENUE OF $207 MILLION AND 31.6% OPERATING MARGIN.Q4 GAAP EARNINGS PER SHARE $1.60.Q4 REVENUE $207.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $218.9 MILLION.SEES FY 2020 REVENUE UP 17 TO 23 PERCENT.SEES FY 2020 REVENUE $900 MILLION TO $945 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $1.08 -- REFINITIV IBES DATA.SAYS "Q4 DID NOT MEET OUR EXPECTATIONS".COMPANY IS GIVING ITS FISCAL YEAR 2020 GUIDANCE FOR GAAP OPERATING MARGIN TO BE IN RANGE OF 29% TO 31%.FY2020 REVENUE VIEW $988.7 MILLION -- REFINITIV IBES DATA.  Full Article

Abiomed Reports 6 Pct Stake In Shockwave Medical
Friday, 22 Mar 2019 

March 22 (Reuters) - Abiomed Inc ::ABIOMED REPORTS 6 PERCENT STAKE IN SHOCKWAVE MEDICAL AS OF MARCH 11 - SEC FILING.ABIOMED- ACQUIRED SHOCKWAVE SHARES ON ASSESSMENT OF POTENTIAL SYNERGIES BETWEEN CO, SHOCKWAVE PRODUCT OFFERINGS, BELIEF IT IS "ATTRACTIVE INVESTMENT".ABIOMED - MAY SEEK TO ENGAGE IN TALKS WITH SHOCKWAVE ABOUT POTENTIAL BUSINESS DEALS.  Full Article

Abiomed Receives FDA Approval For Impella Cp® With Smartassist™ And Optical Sensor
Monday, 2 Apr 2018 

April 2 (Reuters) - Abiomed Inc ::ABIOMED RECEIVES FDA APPROVAL FOR IMPELLA CP® WITH SMARTASSIST™ AND OPTICAL SENSOR.MARKET APPROVAL FOR ITS IMPELLA CP HEART PUMP WITH SMARTASSIST.  Full Article

Abiomed To Appoint Todd Trapp Chief Financial Officer
Friday, 30 Mar 2018 

March 30 (Reuters) - Abiomed Inc ::ABIOMED TO APPOINT NEW CHIEF FINANCIAL OFFICER TODD A. TRAPP.ABIOMED INC - ‍TODD A. TRAPP WILL BE APPOINTED AS VICE PRESIDENT AND CFO, EFFECTIVE APRIL 9, 2018​.  Full Article

Abiomed Receives Approval For Expanded FDA Indication For High Risk PCI Procedures
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - Abiomed Inc ::ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR HIGH RISK PERCUTANEOUS CORONARY INTERVENTION (PCI) PROCEDURES.  Full Article

Abiomed Receives Approval For Expanded FDA Indication For Cardiomyopathy With Cardiogenic Shock
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Abiomed Inc ::ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR CARDIOMYOPATHY WITH CARDIOGENIC SHOCK.ABIOMED INC - APPROVAL EXPANDS PREVIOUS FDA INDICATION FOR ACUTE MYOCARDIAL INFARCTION CARDIOGENIC SHOCK AND PCCS, RECEIVED IN APRIL 2016.  Full Article

Abiomed Reports Q3 Adjusted Earnings Per Share $0.70
Thursday, 1 Feb 2018 

Feb 1 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES Q3 FY 2018 RECORD REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR.Q3 GAAP EARNINGS PER SHARE $0.29.Q3 REVENUE $154 MILLION VERSUS I/B/E/S VIEW $147.9 MILLION.Q3 EARNINGS PER SHARE VIEW $0.50 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE ABOUT $583 MILLION.SEES FY 2018 REVENUE UP ABOUT 31 PERCENT.SEES Q4 2018 REVENUE ABOUT $164 MILLION.Q3 ADJUSTED EARNINGS PER SHARE $0.70.COMPANY IS INCREASING FISCAL YEAR 2018 GUIDANCE FOR GAAP OPERATING MARGIN TO APPROXIMATELY 26%.FY2018 REVENUE VIEW $575.4 MILLION -- THOMSON REUTERS I/B/E/S.Q4 REVENUE VIEW $162.0 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Abiomed Q3 Gaap Earnings Per Share $0.29
Thursday, 1 Feb 2018 

Feb 1 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES Q3 FY 2018 RECORD REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR.Q3 GAAP EARNINGS PER SHARE $0.29.Q3 REVENUE $154 MILLION VERSUS I/B/E/S VIEW $147.9 MILLION.Q3 EARNINGS PER SHARE VIEW $0.50 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE ABOUT $583 MILLION.SEES FY 2018 REVENUE UP ABOUT 31 PERCENT.SEES Q4 2018 REVENUE ABOUT $164 MILLION.Q3 ADJUSTED EARNINGS PER SHARE $0.70.‍ INCREASING FISCAL YEAR 2018 GUIDANCE FOR GAAP OPERATING MARGIN TO ABOUT 26%​.  Full Article

Abiomed Reports Preliminary Q3 FY 2018 Revenue Of $154 Mln, Up 34 Pct Over Prior Year
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES PRELIMINARY Q3 FY 2018 REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR.Q3 REVENUE $154 MILLION VERSUS I/B/E/S VIEW $147.9 MILLION.  Full Article

US STOCKS-Wall St inches higher with earnings in spotlight

* Indexes up: Dow 0.02%, S&P 0.20%, Nasdaq 0.47% (Updates to open)